Company Management will be presenting and holding one-on-one meetings at the Wedbush PacGrow Healthcare Conference. Date & Time: 16 August 2017 at…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update
– Patient Enrollment Progressing for late stage clinical programs in Assisted Reproductive Technology, Uterine Fibroids, and Endometriosis – Geneva, Switzerland and Boston,…
ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017
Geneva, Switzerland and Boston, MA – 07 August, 2017 – ObsEva SA (NASDAQ: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…
A placebo-controlled, randomized, double-blind study of pregnancy and live birth rates after single oral administration of a novel oxytocin antagonist, nolasiban, prior to embryo transfer
H. Tournaye, A. Humberstone, V. Lecomte, P. Terrill, P. Pierzynski, E. Loumaye
ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract O-024: Page i12
Combination tocolytics on the inhibition of OT-induced contractions of human pregnant myometrium in vitro
L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou
ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract O-119: Page i54
FP receptor antagonist, OBE002, inhibits both PGF2α- and OT-induced contractions of human pregnant myometrium in vitro
L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou
ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract P-692: Page i452
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART Non-clinical results of OBE022…
Q2 2017 ObsEva SA Earnings Conference call
ObsEva to report financial results for the second quarter on Tuesday, August 15, 2017 Date & Time: 15 August 2017 at…
ObsEva Annual General Meeting 2017
Tuesday, June 13, 2017 Location: Geneva Supporting Materials:
ObsEva Annual General Meeting
Supporting Materials Invitation to the Annual General Meeting of Shareholders ObsEva 2017 Equity Incentive Plan Annual Report Date & Time: Tuesday,…